{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx2",
      "pmids":[
        "25957392"
      ],
      "tumorType":{
        "children":{},
        "code":"MDS",
        "color":"LightSalmon",
        "id":355,
        "level":3,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic Syndromes",
          "tumorForm":"LIQUID"
        },
        "name":"Myelodysplastic Syndromes",
        "parent":"MNM",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "24550227",
        "22150006",
        "23415222",
        "26200345",
        "22039264",
        "26466571"
      ],
      "tumorType":{
        "children":{},
        "code":"CLLSLL",
        "color":"LimeGreen",
        "id":533,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx2",
      "pmids":[
        "22096241",
        "25957392"
      ],
      "tumorType":{
        "children":{},
        "code":"MDSRS",
        "color":"LightSalmon",
        "id":267,
        "level":4,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic Syndromes",
          "tumorForm":"LIQUID"
        },
        "name":"MDS with Ring Sideroblasts",
        "parent":"MDS",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx2",
      "pmids":[
        "19692701",
        "25957392"
      ],
      "tumorType":{
        "children":{},
        "code":"MDSMPNRST",
        "color":"LightSalmon",
        "id":801,
        "level":4,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic/Myeloproliferative Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"MDS/MPN with Ring Sideroblasts and Thrombocytosis",
        "parent":"MDS/MPN",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"SF3B1, a component of the spliceosome complex, is frequently mutated in hematologic malignancies.",
  "highestDiagnosticImplicationLevel":"LEVEL_Dx2",
  "highestFdaLevel":"LEVEL_Fda3",
  "highestPrognosticImplicationLevel":"LEVEL_Px1",
  "highestResistanceLevel":null,
  "highestSensitiveLevel":"LEVEL_4",
  "hotspot":true,
  "lastUpdate":"02/23/2023",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "33031100",
        "24434863",
        "26565915",
        "23861464"
      ]
    },
    "description":"The SF3B1 R625C mutation occurs in the protein\u2019s HEAT domain, which functions as a scaffolding region for protein interactions. This mutation has been found in uveal melanoma (UVM) (PMID: 33031100). Mutations within this domain alter SF3B1-mediated splicing, resulting in the degradation of SF3B1-targeted transcripts and aberrant protein expression in the cell (PMID: 26565915). In patient-derived UVM and myelodysplastic syndrome samples, the R625C mutation has been found to alter the splicing and gene expression signatures (PMID: 23861464, 24434863).",
    "knownEffect":"Switch-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Px1",
      "pmids":[
        "21998214"
      ],
      "tumorType":{
        "children":{},
        "code":"MDS",
        "color":"LightSalmon",
        "id":355,
        "level":3,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic Syndromes",
          "tumorForm":"LIQUID"
        },
        "name":"Myelodysplastic Syndromes",
        "parent":"MNM",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Px1",
      "pmids":[
        "23594705",
        "21998214"
      ],
      "tumorType":{
        "children":{},
        "code":"MDSMPNRST",
        "color":"LightSalmon",
        "id":801,
        "level":4,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic/Myeloproliferative Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"MDS/MPN with Ring Sideroblasts and Thrombocytosis",
        "parent":"MDS/MPN",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Px2",
      "pmids":[
        "30594750",
        "29296692"
      ],
      "tumorType":{
        "children":{},
        "code":"ET",
        "color":"LightSalmon",
        "id":695,
        "level":4,
        "mainType":{
          "id":null,
          "name":"Myeloproliferative Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Essential Thrombocythemia",
        "parent":"MPN",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "prognosticSummary":"",
  "query":{
    "alteration":"R625C",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":23451,
    "hgvs":"2:g.197402760G>A",
    "hugoSymbol":"SF3B1",
    "id":null,
    "proteinEnd":625,
    "proteinStart":625,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[
    {
      "abstracts":[
        {
          "abstract":"Buonamici et al. Abstract# 636, ASH, 2016",
          "link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true"
        }
      ],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"H3B-8800 is an orally available small-molecule modulator of the SF3b complex. Specifically, H3B-8800 modulates splicing by interfering with the interaction between the SF3b complex and the branchpoint region on RNA. Preclinical studies show that spliceosome-mutants are sensitive to H3B-8800 treatment, as measured by decreased proliferation in spliceosome-mutant acute myeloid leukemia cell lines and xenograft models and decreased cell proliferation and viability in pancreatic cancer cell lines upon drug treatment compared to isogenic controls expressing a wildtype spliceosome (PMID: 29457796)(Abstract: Buonamici et al. Abstract# 636, ASH, 2016. http://www.bloodjournal.org/content/128/22/966?sso-checked=true).",
      "drugs":[
        {
          "drugName":"H3B-8800",
          "ncitCode":"C129546",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"AML",
        "color":"LightSalmon",
        "id":527,
        "level":3,
        "mainType":{
          "id":null,
          "name":"Leukemia",
          "tumorForm":"LIQUID"
        },
        "name":"Acute Myeloid Leukemia",
        "parent":"MNM",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[
        "29457796"
      ]
    },
    {
      "abstracts":[
        {
          "abstract":"Buonamici et al. Abstract# 636, ASH, 2016",
          "link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true"
        }
      ],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"H3B-8800 is an orally available small-molecule modulator of the SF3b complex. Specifically, H3B-8800 modulates splicing by interfering with the interaction between the SF3b complex and the branchpoint region on RNA. Preclinical studies show that spliceosome-mutants are sensitive to H3B-8800 treatment, as measured by decreased proliferation in spliceosome-mutant acute myeloid leukemia cell lines and xenograft models and decreased cell proliferation and viability in pancreatic cancer cell lines upon drug treatment compared to isogenic controls expressing a wildtype spliceosome (PMID: 29457796)(Abstract: Buonamici et al. Abstract# 636, ASH, 2016. http://www.bloodjournal.org/content/128/22/966?sso-checked=true).",
      "drugs":[
        {
          "drugName":"H3B-8800",
          "ncitCode":"C129546",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"CMML",
        "color":"LightSalmon",
        "id":224,
        "level":4,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic/Myeloproliferative Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Chronic Myelomonocytic Leukemia",
        "parent":"MDS/MPN",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[
        "29457796"
      ]
    },
    {
      "abstracts":[
        {
          "abstract":"Buonamici et al. Abstract# 636, ASH, 2016",
          "link":"http://www.bloodjournal.org/content/128/22/966?sso-checked=true"
        }
      ],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"H3B-8800 is an orally available small-molecule modulator of the SF3b complex. Specifically, H3B-8800 modulates splicing by interfering with the interaction between the SF3b complex and the branchpoint region on RNA. Preclinical studies show that spliceosome-mutants are sensitive to H3B-8800 treatment, as measured by decreased proliferation in spliceosome-mutant acute myeloid leukemia cell lines and xenograft models and decreased cell proliferation and viability in pancreatic cancer cell lines upon drug treatment compared to isogenic controls expressing a wildtype spliceosome (PMID: 29457796)(Abstract: Buonamici et al. Abstract# 636, ASH, 2016. http://www.bloodjournal.org/content/128/22/966?sso-checked=true).",
      "drugs":[
        {
          "drugName":"H3B-8800",
          "ncitCode":"C129546",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"MDS",
        "color":"LightSalmon",
        "id":355,
        "level":3,
        "mainType":{
          "id":null,
          "name":"Myelodysplastic Syndromes",
          "tumorForm":"LIQUID"
        },
        "name":"Myelodysplastic Syndromes",
        "parent":"MNM",
        "tissue":"Myeloid",
        "tumorForm":"LIQUID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[
        "29457796"
      ]
    }
  ],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The SF3B1 R625C mutation is likely oncogenic.",
  "vus":false
}